Progenics Pharmaceuticals (PGNX) Getting Somewhat Favorable News Coverage, Analysis Finds
Press coverage about Progenics Pharmaceuticals (NASDAQ:PGNX) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.06 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.2994463250002 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 5th. ValuEngine downgraded shares of Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Cantor Fitzgerald set a $15.00 target price on shares of Progenics Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, May 20th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $13.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. Finally, Needham & Company LLC reaffirmed a “strong-buy” rating and issued a $14.00 target price on shares of Progenics Pharmaceuticals in a report on Wednesday, August 1st. Two investment analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $12.19.
Shares of Progenics Pharmaceuticals stock opened at $7.36 on Monday. The firm has a market capitalization of $554.64 million, a P/E ratio of -8.18 and a beta of 2.40. The company has a quick ratio of 6.34, a current ratio of 6.34 and a debt-to-equity ratio of 0.68. Progenics Pharmaceuticals has a fifty-two week low of $5.01 and a fifty-two week high of $9.42.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.
Featured Article: What is the NASDAQ?
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.